目的  探讨 survivin mRNA 在结直肠癌患者外周血的表达及临床意义。方法  采用 SPSS16.0 软件进行统计分析。采 取 χ2 检验 ，收集保定市第一中心医院普通外科收治的结直肠癌患者90 例、结直肠腺瘤疾病患者60 例，同期选择本院体检 健康人60 例为对照组，运用巢式RT-PCR 技术检测并比较术前结直肠癌患者、结直肠腺瘤疾病患者、正常健康人3组血清 中survivin mRNA 表达水平。分析结直肠癌患者血清中survivin mRNA 水平与肿瘤术后分期、病理类型、分化程度和是否远 处转移等临床病理特征相关性。结果  健康人中 survivin mRNA 不表达，结直肠良性腺瘤疾病患者中有 2例survivin mRNA 表达，表达率为3.33%，结直肠癌患者外周血中survivin mRNA 有49 例，表达率为54.44%，survivin mRNA 表达率与肿瘤分期 及肿瘤转移密切相关（P＜0.05），与肿瘤的病理类型及分化程度无明显相关（P＞0.05）。结论  结直肠癌患者外周 survivin mRNA 表达明显上调，其与结肠癌分期及是否远处转移密切相关，可以作为检测结直肠癌患者外周血转移和评价肿瘤是否进 展的良好的分子标记物。

 Objective  To explore the expression of survivin mRNA in peripheral blood of patients with colorectal cancer and its clinical significance. Methods  SPSS16.0 software was used for statistical analysis. χ2 test was used. Collected 90 patients with colorectal cancer and 60 patients with colorectal adenoma disease in general surgery of baoding first central hospital. 60 healthy people were selected as control group during the same period. The expression of Survivin in serum of patients with colorectal cancer, patients with colorectal adenoma disease and healthy controls before operation was detected and compared by nested RT-PCR. To analyze the correlation between the level of Survivin mRNA in serum of patients with colorectal cancer and clinicopathological features such as stage, pathological type, degree of differentiation and distant metastasis after operation. Results  Survivin was not expressed in healthy people. Survivin was expressed in 2 patients with benign colorectal adenoma (3.33%) and 49 patients with colorectal cancer (54.44%) in peripheral blood. The expression rate of survivin was closely related to tumor stage and distant metastasis (P<0.05). Significant correlation (P>0.05). Conclusions  The expression of survivin in peripheral blood of patients with colorectal cancer is significantly up-regulated, which is closely related to the stage and distant metastasis of colorectal cancer. It can be used as a good molecular marker to detect metastasis in peripheral blood of patients with colorectal cancer and to evaluate the progress of cancer.